Business Wire

ABB and Kawasaki Announce Collaborative Robot Automation Cooperation

Del

ABB and Kawasaki Heavy Industries, two global industrial automation and robot suppliers, announced today that the companies will join forces to share knowledge and promote the benefits of collaborative robots, in particular those with dual arm designs. The global cooperation will become effective immediately.

Under the new cooperation, which is the world’s first to focus on ‘cobots,’ both robot makers will continue independently manufacturing and marketing their own offerings while working together on joint technical and awareness opportunities. This includes educating policy makers, NGOs and the general public about the benefits of collaborative automation, and creating common industry approaches to safety, programming and communications.

Collaboration between people and robots, machines and processes is increasingly important as production in many industries has shifted from larger lots with little variation to low volumes with a high mix. This means more variability and more human intervention. Collaborative automation allows people and robots to each contribute their unique strengths – people offer process knowledge, insight and improvisation for change, while robots offer tireless endurance for repetitive tasks.

The cooperation also represents collaboration across borders, with ABB as Europe’s largest robot supplier and Kawasaki one of Asia’s industrial giants. “The scale and pace of change in the robotics industry today is unimaginable,” said Per Vegard Nerseth, Managing Director of ABB’s Robotics business. “Beyond the technologies behind collaborative automation, there is also a need for innovative new ways of working together and creating common industry approaches to safety, programming and communications.”

“Collaborative robots, especially those with two arms capable of human interactions, can greatly contribute to society and help the world cope with labor shortages and an aging workforce. We see high potential in expanding collaborative applications and processes where people and technology work together to create solutions,” said Yasuhiko Hashimoto, Managing Executive Officer and General Manager, Kawasaki Robot Division. “I’m very pleased that ABB and Kawasaki are joining forces to lead the drive for more user-friendly, advanced collaborative automation.”

ABB is recognized as a pioneer in collaborative automation through its YuMi dual arm robot, the world’s first truly collaborative robot. The YuMi robot makes it possible for people and robots to safely share common tasks such as assembling small electronics.

Kawasaki is offering a very unique and innovative Dual-Arm SCARA Robot “duAro”, which has been developed based on extensive application know-how and which can safely collaborate with humans in the workplace.

The first output from this cooperation will be a collaborative dual arm robot demonstration in Booth IR3-56, IR5-22 and SR-82 at IREX, to be held in Tokyo, Japan from November 29 to December 2, 2017.

ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing a more than 125-year history of innovation, ABB today is writing the future of industrial digitalization and driving the Energy and Fourth Industrial Revolutions. ABB operates in more than 100 countries with about 136,000 employees. www.abb.com

ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 300,000 robot solutions in a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics

Kawasaki was founded more than 120 years ago and has been developing globally while producing revolutionary products by working together to ensure technology synergies across its different divisions.

Kawasaki is now recognized as a global leader in diverse industries in wide ranging fields going beyond land, sea and air, offering state-of-the-art technologies for environmental and energy infrastructure, machinery and robotics, and various types of transportation in marine, railway and aerospace to a leisure vehicles as motorcycles and personal watercraft in global basis with about 35,200 employees. global.kawasaki.com

Kawasaki Robotics is a leading supplier of industrial robots and robot automation systems with a broad product portfolio having shipped 170,000 robots in about 50 countries. As a pioneer in Japan, Kawasaki celebrates its 50th anniversary in 2017. As one of the world’s leading robotics suppliers, we are now transforming ourselves from an industrial to a fully integrated robot supplier. Kawasaki is a solution provider having deep application know-how through diverse business and products on land, sea and air. robotics.kawasaki.com

Contact information

ABB Media Relations
+41 43 317 71 11
media.relations@ch.abb.com
or
ABB Investor Relations
+41 43 317 71 11
investor.relations@ch.abb.com
or
Kawasaki Media Relations
webadmin@khi.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 09:00Pressemelding

AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product

Rivoli Group announces completion of its new international corporate strategy15.6.2018 07:00Pressemelding

Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings